Abstract 1027P
Background
GI-101 is a novel immunocytokine containing CD80 and IL-2v. GI-101 monotherapy and with pembrolizumab have demonstrated early signs of anti-tumor activities in the ongoing GII-101-P101 study1. Here we report clinical outcomes from Part A (GI-101 monotherapy) of the study with additional patients (pts) treated.
Methods
GII-101-P101 study is a 4-part, first-in-human, phase 1/2 study of GI-101 monotherapy and in combination with various agents in pts with advanced solid tumors. In Part A, dose escalation with 3+3 design established the recommended phase 2 dose (RP2D) and is followed by expansion cohort. Primary endpoints include safety, tolerability and investigator-assessed objective response.
Results
At the data cut-off of 20 Apr 2023, 57 pts received GI-101 monotherapy (19 in escalation and 38 in expansion cohorts). The median number of prior therapies were 3 [1–11] and 47% were previously experienced immunotherapy. No dose-limiting toxicities (DLTs) were reported in escalation cohort (0.002∼0.3 mg/kg) and maximum tolerated dose (MTD) was not reached. The dose of 0.3 mg/kg GI-101 Q3W was established as the RP2D. Treatment-emergent adverse events (TEAEs) occurred in 55 pts (96%); the most common (>30%) were pyrexia (67%) and transient AST increase (37%). Objective responses were observed in 3/50 evaluable pts regardless of prior anti-PD-(L)1 therapy; 1 confirmed CR (cervical cancer), 1 confirmed PR (UBC) and 1 unconfirmed PR (NSCLC) with 1 CR is ongoing (144+ days). Disease control rate is 46% and median PFS [min-max] was 41 [21-294] days. Meaningful target lesion reduction at 54W (-53%; on-treatment > 429+ days) was observed in MSS CRC with liver metastasis. GI-101 resulted in robust expansion of peripheral lymphocyte at RP2D, median 3.4-fold [2.0-8.4], primarily CD8+ T, NK, effector and central memory T cells, but not Tregs. Lymphocyte expansion was correlated with increased PFS (P=0.00515).
Conclusions
GI-101 was well tolerated as monotherapy. Monotherapy activity was seen regardless of previous immunotherapy experience, with a favorable benefit to risk profile. The other parts of the trial with pembrolizumab, lenvatinib and radiation continue to enroll.
Clinical trial identification
NCT04977453.
Editorial acknowledgement
Legal entity responsible for the study
GI Innovation, Inc.
Funding
GI Innovation, Inc. Korea Drug Development Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19